The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity. The Series C financing ...
Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...